BOTANIX PHARMACEUTICALS LTD — Capital/Financing Update 2022

Nov 6, 2022

==> picture [114 x 50] intentionally omitted <==

7 November 2022

Cleansing Notice Under Section 708A(5)(e) of the Corporations Act 2001 and ASIC Corporations (Share And Interest Purchase Plans) Instrument 2019/547

Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”) wishes to confirm the issue of 70,717,484 million fully paid ordinary shares in the Company (New Shares) on 7 November 2022 at an issue price of $0.063 per New Share to Antares Capital under the first tranche of the placement announced on Monday, 31 October 2022.

The Company hereby provides notification under section 708A(5)(e) of the Corporations Act 2001 (Cth) ( Act ) of the issue. The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or section 708A of the Act. Through the release of this notice by the Company, a sale of the New Shares will fall within the exemption in section 708A(5) of the Act and they will be able to be traded immediately.

The Company also hereby provides notification under the ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 ( ASIC Instrument ). The Company is offering fully paid ordinary shares under a Share Purchase Plan ( SPP ) to raise up to $3 million (before costs). The SPP will be offered in accordance with the ASIC Instrument and a SPP booklet will be dispatched to eligible shareholders of the Company.

For the purposes of section 708A(6) of the Act and the Instrument, the Company gives notice that:

• (a) the Company issued the New Shares under the first tranche of the Placement and will make offers to issue fully paid ordinary shares under the SPP, without disclosure to investors under Part 6D.2 of the Act;

• (b) this notice is being given under section 708A(5)(e) of the Act;

• (c) as at the date of this notice, the Company has complied with:

  • (i) the provisions of Chapter 2M of the Act as they apply to the Company; and

  • (ii) sections 674 and 674A of the Act; and

• (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meaning of sections 708A(7) and 708A(8) of the Act that is required to be set out in this notice.

This ASX announcement is authorised for release by the Board

==> picture [113 x 50] intentionally omitted <==

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is committed to the development of novel treatments for a range of common skin diseases. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis, filed for FDA approval in Q3 CY2022 with approval expected in Q3 2023. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis.

Botanix leverages its proprietary drug delivery system (Permetrex[TM] ) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries Investor enquiries Media enquiries Corporate Communications Hannah Howlett Haley Chartres Botanix Pharmaceuticals WE Communications H^CK P: +61 8 6555 2945 P: +61 450 648 064 P: +61 423 139 163 investors@botanixpharma.com hhowlett@we-worldwide.com haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company’s ability to obtain marketing approvals for is product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of Sofpironium Bromide and the market for Sofpironium Bromide. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

==> picture [113 x 50] intentionally omitted <==

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.